Zynerba Pharmaceuticals, Inc.

ZYNE


Canadian symbol: ZYNE
US symbol: ZYNE

Currency in USD

Valuation Measures

Market Cap (intraday) 593.07M
Enterprise Value 325.45M
Trailing P/E N/A
Forward P/E 1-2.45
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.33
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-0.72

Trading Information

Stock Price History

Beta (5Y Monthly) 3.09
52-Week Change 3-73.24%
S&P500 52-Week Change 35.66%
52 Week High 314.2790
52 Week Low 32.5500
50-Day Moving Average 35.1907
200-Day Moving Average 34.6682

Share Statistics

Avg Vol (3 month) 31.78M
Avg Vol (10 day) 32.44M
Shares Outstanding 524.95M
Float 22.83M
% Held by Insiders 112.32%
% Held by Institutions 146.94%
Shares Short (Jun. 14, 2020) 46.79M
Short Ratio (Jun. 14, 2020) 44.5
Short % of Float (Jun. 14, 2020) 431.41%
Short % of Shares Outstanding (Jun. 14, 2020) 427.21%
Shares Short (prior month May 14, 2020) 45.76M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-29.32%
Return on Equity (ttm)-53.85%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -35.51M
Net Income Avi to Common (ttm)-36.13M
Diluted EPS (ttm)-1.5720
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)60.64M
Total Cash Per Share (mrq)2.43
Total Debt (mrq)296.63k
Total Debt/Equity (mrq)0.45
Current Ratio (mrq)7.31
Book Value Per Share (mrq)2.81

Cash Flow Statement

Operating Cash Flow (ttm)-36.3M
Levered Free Cash Flow (ttm)-22.66M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
ZYNE
Zynerba Pharmaceuticals
1 week ago
ZYNE
Zynerba Pharmaceuticals
1 month ago
ZYNE
Zynerba Pharmaceuticals
4 months ago
ZYNE
Zynerba Pharmaceuticals
4 months ago
ZYNE
Zynerba Pharmaceuticals
4 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago
ZYNE
Zynerba Pharmaceuticals
6 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
7 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
8 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
9 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
11 months ago
ZYNE
Zynerba Pharmaceuticals
12 months ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago
ZYNE
Zynerba Pharmaceuticals
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts7777
Avg. Estimate-0.45-0.43-1.8-1.52
Low Estimate-0.47-0.51-1.97-2.1
High Estimate-0.41-0.36-1.43-1.18
Year Ago EPS-0.5-0.08-1.5-1.8
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts6677
Avg. EstimateN/AN/AN/A2.86M
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/A20M
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.5-0.52-0.5-0.5
EPS Actual-0.5-0.08-0.46-0.53
Difference00.440.04-0.03
Surprise %0.00%84.60%8.00%-6.00%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate-0.45-0.43-1.8-1.52
7 Days Ago-0.45-0.43-1.8-1.52
30 Days Ago-0.45-0.42-1.8-1.6
60 Days Ago-0.48-0.44-1.82-1.57
90 Days Ago-0.48-0.44-1.82-1.57
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 Days2134
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesZYNEIndustrySector(s)S&P 500
Current Qtr.10.00%N/AN/AN/A
Next Qtr.-437.50%N/AN/AN/A
Current Year-20.00%N/AN/AN/A
Next Year15.60%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
12.32%% of Shares Held by All Insider
46.94%% of Shares Held by Institutions
53.54%% of Float Held by Institutions
113Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Vanguard Group, Inc. (The)1,609,217Mar. 30, 20206.45%6,163,301
Blackrock Inc.1,508,608Mar. 30, 20206.05%5,777,968
ETF Managers Group, LLC1,208,126Mar. 30, 20204.84%4,627,122
Portolan Capital Management, LLC434,768Mar. 30, 20201.74%1,665,161
State Street Corporation424,725Mar. 30, 20201.70%1,626,696
Zeke Capital Advisors LLC402,212Mar. 30, 20201.61%1,540,471
AdvisorShares Investments, LLC352,968Mar. 30, 20201.41%1,351,867
Prentice Capital Management, LP341,436Mar. 30, 20201.37%1,307,699
Northern Trust Corporation329,381Mar. 30, 20201.32%1,261,529
Mirae Asset Global Investments Co., Ltd.313,827Mar. 30, 20201.26%1,201,957

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
ETF Managers Tr-EFTMG Alternative Harvest ETF1,208,126Mar. 30, 20204.84%4,627,122
Vanguard Total Stock Market Index Fund630,140Mar. 30, 20202.53%2,413,436
Vanguard Explorer Fund, Inc.545,001Apr. 29, 20202.18%2,109,153
iShares Russell 2000 ETF497,490Apr. 29, 20201.99%1,925,286
Fidelity Strategic Advisors Small-Mid Cap Fund373,391Feb. 28, 20201.50%1,590,645
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF352,968Mar. 30, 20201.41%1,351,867
Vanguard Extended Market Index Fund294,492Mar. 30, 20201.18%1,127,904
iShares Russell 2000 Growth ETF199,673Apr. 29, 20200.80%772,734
Fidelity Small Cap Index Fund134,886Apr. 29, 20200.54%522,008
Fidelity Extended Market Index Fund95,492Apr. 29, 20200.38%369,554
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Zynerba Pharmaceuticals, Inc.


Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Top Line Results from Pivotal CONNECT-FX Trial of Zygel™ (CBD Gel) in Fragile X Syndrome

- Study Did Not Achieve Statistical Significance in Primary or Key Secondary Endpoints in Full Analysis Set -- Achieved Statistical Significance on Primary Endpoint (p=0.020) in Pre-Planned Ad Hoc Analysis of Patients with Full Methylation of the FMR1 Gene Comprising 80% of the Study Population - - Zynerba to host conference call and webc... Read More...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder

- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist -- Safety Data Reinforce Excellent Tolerability Profile of Zygel - - Zynerba to host conference call and webcast today, May 27, 2020 at 8:30 am ET - DEVON, Pa., May 27, 2020 -- Zyne... Read More...
Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

Zynerba Pharmaceuticals Announces New Two-Year Data from Open Label Extension of the Phase 2 FAB-C Trial in Patients with Fragile X at 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

- Robust Response Sustained through Two Years of Treatment with Zygel™ in Patients from Phase 2 FAB-C Trial -- Top Line Results of Pivotal CONNECT-FX Trial Expected Late in the Second Quarter of 2020 - DEVON, Pa., May 26, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal ca... Read More...
Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

Zynerba Pharmaceuticals Announces Presentation of Phase 2 BELIEVE Safety, Efficacy and Quality of Life Data in Developmental and Epileptic Encephalopathies (DEE) at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Session

DEVON, Pa., May 26, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters on the safety, efficacy and quality of life results of the Phase 2 BELIEVE (Open Label Study to Assess th... Read More...
Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

Zynerba Pharmaceuticals Changes Annual Meeting of Shareholders to Virtual-Only Format in Response to COVID-19 Pandemic

DEVON, Pa., May 21, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that due to public health guidance related to the coronavirus (COVID-19) pandemic and for the safety of participant... Read More...
Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights

DEVON, Pa., May 11, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2020 and provided an overview of recent operational highligh... Read More...
Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

Zynerba Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference

DEVON, Pa., April 10, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 19th Annual Needham ... Read More...
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

- Key Recent Clinical Milestones Include Completion of Enrollment in Pivotal CONNECT-FX Trial in Fragile X Syndrome and Phase 2 BRIGHT Trial in Autism Spectrum Disorder -DEVON, Pa., March 10, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare a... Read More...
Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting

Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting

DEVON, Pa., March 09, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of three posters at the American Academy of Neurology (AAN) 2020 Annual M... Read More...
Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 

Zynerba Pharmaceuticals Presents Health State Utility Index Data on Severity of Fragile X Syndrome (FXS) and Diagnostic Challenges Faced by Caregivers 

- Data Presented at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Meeting -- Health State Utility Index Data Estimate the Significant Health Burden of FXS, and Suggest the Potential Benefit of Treatment with Zygel™ - - Caregiver’s Perspective on Protracted Journey to Diagnosis, Current Standard of Care and Comorbid ... Read More...
Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population

DEVON, Pa., March 03, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting data this week further describing the baseline characteristics of the pediatric and adolescent patients in the full... Read More...
Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel™ in Fragile X Syndrome

DEVON, Pa., Feb. 26, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the Company has completed enrollment in its 14-week pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) i... Read More...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Purified Cannabidiol

DEVON, Pa., Feb. 25, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,568,848, titled “Treatment of Autism with ... Read More...
Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting

Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual Meeting

DEVON, Pa., Feb. 20, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of data being presented at the American Society for Experimental Neurother... Read More...
Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X Syndrome

- Company Expects to Complete Randomization in February 2020 -- Topline Results from Pivotal CONNECT-FX Study Remain On Track for the Second Quarter of 2020 - DEVON, Pa., Feb. 03, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare... Read More...
Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X Syndrome

DEVON, Pa., Jan. 13, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today provided an update on the pivotal CONNECT-FX (Clinical study of Cannabidiol (CBD) in Children and Adolescents with Fragile X... Read More...
Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum Disorder

DEVON, Pa., Jan. 13, 2020 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the achievement of its enrollment target for the 14-week Phase 2 BRIGHT (An Open-Label Tolerability and Efficacy S... Read More...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol

DEVON, Pa., Nov. 12, 2019 -- Zynerba Pharmaceuticals, Inc. (ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,471,022, titled “Treatment of Fragile X Syndrome wi... Read More...
Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

- Positive Topline Results from BELIEVE 1 Phase 2 Trial of Zygel™ in Children and Adolescents with Developmental and Epileptic Encephalopathies Suggest Compelling Seizure Reductions and Excellent Tolerability -- Topline Results from Pivotal Trial in Fragile X Syndrome On Track for 1H2020 -- Phase 2 Topline Results in Autism Spectrum Disor... Read More...
Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

DEVON, Pa., Sept. 26, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the 2019 Cantor Global H... Read More...
New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)

- Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS -- New Data Presented Today at the Society for the Study of Behavioural Phenotypes (SSBP) Research Symposium - DEVON, Pa., Sept. 05, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the le... Read More...
Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium

DEVON, Pa., Aug. 29, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of two posters at the 22nd Society for the Study of Behavioural Pheno... Read More...
Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Announces Publication of Zygel™ (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders

DEVON, Pa., Aug. 06, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the publication of data from the Phase 2 FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges ... Read More...
Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights

DEVON, Pa., Aug. 06, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the second quarter ended June 30, 2019 and provided an overview of recent operational highlig... Read More...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol

DEVON, Pa., June 11, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,314,792, titled “Treatment of Autism Spectru... Read More...
Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds

Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds

DEVON, Pa., May 30, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Ray Mannion, Zynerba’s Vice President of Manufacturing, will provide a formal presentation during the U.S. Foo... Read More...
Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

DEVON, Pa., May 29, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that it has initiated the Phase 2 INSPIRE (Assessing the Impact of Zygel on Pediatric Behavioral and Emotional Sy... Read More...
Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

DEVON, Pa., May 28, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Zynerba’s Chief Executive Officer, Armando Anido will present a company overview at the Jefferies 2019 Global ... Read More...
Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

DEVON, Pa., May 08, 2019 -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the first quarter ended March 31, 2019 and provided an overview of recent operational highligh... Read More...
Coming Soon.

Delayed data (1h)


Share this page